文献速递神经免疫

多发性硬化前驱期:首次脱髓鞘事件前的医疗使用模式

Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study.
PubMed 文献 · Lancet Neurol · 2017-04-20

这项匹配队列研究利用加拿大四省卫生行政与临床数据,比较多发性硬化患者在首次脱髓鞘事件前5年与匹配对照的医疗使用。行政队列显示住院、医生服务和处方使用比值比从第5年至第1年逐渐升高,临床队列模式相似但多数未达统计学显著,提示多发性硬化前驱期存在。

要点

  • 多发性硬化患者在首次脱髓鞘事件前5年医疗使用已高于匹配对照。
  • 住院、医生服务和处方使用的比值比随接近首次事件而逐渐升高。
  • 临床队列中医生服务和处方使用模式相似,但多数差异未达统计学显著。

核心结论

  • 多发性硬化患者在首次脱髓鞘事件前5年医疗使用较对照更频繁,提示存在可测量的多发性硬化前驱期。

研究设计与样本

  • 匹配队列研究,使用加拿大四省关联卫生行政与临床数据库,比较多发性硬化患者与匹配一般人群对照在首次脱髓鞘疾病索赔或临床报告症状 onset 前5年的医疗使用。
  • 使用负二项回归估计率比(RR),并以随机效应模型合并各省结果。

主要发现

  • 行政队列中,首次脱髓鞘疾病索赔前5年至前1年,多发性硬化患者较对照的年度医疗使用稳步增加。
  • 临床队列中医生服务和处方使用模式相似,但5年中各年差异大多未达统计学显著。

临床怎么用

  • 临床中应关注首次脱髓鞘事件前数年医疗使用增加的现象,有助于更早识别潜在多发性硬化患者。
  • 该前驱期窗口可能为早期干预和潜在治疗提供机会。

局限性

  • 临床队列中多数年度差异未达统计学显著,需谨慎解读。
  • 研究基于卫生行政数据,可能受数据记录和索赔定义影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Degenerative processes in neurodegenerative diseases can start years before clinical manifestation. We aimed to establish whether a multiple sclerosis prodromal period exists by examining patterns of health-care use before a first demyelinating event. METHODS: In this matched cohort study, we used data from linked health administrative and clinical databases from four Canadian provinces (British Columbia, Saskatchewan, Manitoba, and Nova Scotia) to compare hospital, physician, and prescription use data from people with multiple sclerosis and matched general population controls in the 5 years before the first demyelinating disease claim (health administrative index date) or clinically reported symptom onset (clinical index date). Rate ratios (RRs) were estimated using negative binomial regression and combined across provinces using random effect models. The primary outcome was all-cause use of health care during each of the 5 years before the health administrative or clinical index date. FINDINGS: The health administrative cohort included 14 428 multiple sclerosis cases and 72 059 matched controls for whom data were available between April, 1984, and April, 2014. Annual health-care use increased steadily between 5 years and 1 year before the first demyelinating disease claim in people with multiple sclerosis compared with controls (from RR 1·26 [95% CI 1·16-1·36] to 1·78 [1·50-2·10] for hospital admissions; from 1·24 [1·16-1·32] to 1·88 [1·72-2·07] for physician claims; and from 1·23 [1·06-1·41] to 1·49 [1·41-1·59] for prescriptions, assessed as drug classes). Similar patterns for physician claims and prescriptions were observed in the cohort with available clinical symptom onset (3202 individuals with multiple sclerosis and 16 006 controls), although the differences in use in each of the 5 years mostly did not reach statistical significance. INTERPRETATION: More frequent use of health care in patients with multiple sclerosis than in controls in the 5 years before a first demyelinating event, according to health administrative data, suggests the existence of a measurable multiple sclerosis prodrome. These findings have clinical and research implications, including the establishment of an earlier window of opportunity to identify and potentially treat multiple sclerosis. FUNDING: National Multiple Sclerosis Society.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Wijnands JMA, Kingwell E, Zhu F, et al. Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study. Lancet Neurol. 2017. PMID: 28434855. doi:10.1016/S1474-4422(17)30076-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。